Wall Street’s crystal ball is looking pretty optimistic these days. Morgan Stanley’s chief equity strategist Michael Wilson just bumped his S&P 500 target from 7,200 to 7,800 by the end of 2026—and honestly, the reasoning behind it is pretty solid.
Here’s the setup: We’re currently sitting around 6,600 on the S&P 500, up about 13% year-to-date. If Wilson’s prediction hits, that’s roughly an 18% return from here. Not too shabby. But here’s the kicker—Wilson isn’t just throwing darts at a board. He’s arguing we’re in a brand new bull market that kicked off in late April after the market got hammered in Q1.
The real story? Corporate earnings are about to go on a tear. Wilson’s team expects S&P 500 earnings to finish 2025 at $272 per share (a 12% jump), then jump to $317 in 2026 (17% gain), and another 12% bump to $356 in 2027. That’s the kind of earnings growth that actually justifies stock prices climbing higher.
What’s fueling this optimistic outlook? A few things are working in the market’s favor. First, there’s positive operating leverage—companies are getting more efficient. Second, AI is delivering real efficiency gains, not just hype. Third, tax and regulatory policies are looking accommodating. And fourth, companies have pricing power, meaning they can actually pass costs to consumers without getting destroyed.
Now, here’s where it gets interesting. Wilson acknowledges that valuations are still relatively high with a P/E ratio around 22. But his argument is that many stocks aren’t actually as expensive as they look when you factor in this earnings growth. Sure, some speculative growth areas might be frothy, but the broader market has room to run.
The Morgan Stanley team also has some sector-specific takes worth noting. They’re bullish on small caps—the Russell 2000 has lagged badly this year, up just 5.8% compared to the S&P 500’s 13%. That’s a potential opportunity. They also like consumer cyclicals over staples, plus financials, industrials, and healthcare.
Healthcare gets special attention because rate cuts into 2026 should help valuations, earnings momentum looks solid, and M&A activity is expected to pick up. Biotech, in particular, tends to perform well 6-12 months after the Fed starts cutting rates.
The bottom line? Wilson’s thesis rests on a simple idea: we’re in the early stages of a new bull market driven by real earnings growth, not just multiple expansion. That’s a meaningful distinction. It means the gains could be sustainable rather than just a sugar rush.
Of course, markets are unpredictable, and plenty can go wrong between now and December 2026. But if you’re looking for a reason to stay bullish, Morgan Stanley just handed you one backed by actual earnings forecasts rather than wishful thinking.
